Figure 2. Risk Differences for 1000 Patients Treated for 3 Years With Evolocumab for the First and Total Number of the Primary End Point.

For every 1000 patients treated for 3 years, 22 first primary end point events and 52 total primary end point events were prevented with evolocumab.